Under the Medicines Australia agreement, PBAC considered an immediate change to the discount rate with implementation planned through updated guidelines from July 2022. That change never arrived. The committee opposed any reduction. Surely that prejudices any role for the committee in the new review. Yes, a new review.
Every new working group and every consultation squeezes more life out of reform, like a lemon wrung to its rind
September 4, 2025 Latest NewsBioPharmaComment
Latest Video
New Stories
-
The 'Dispatched' Podcast - Week in review
August 7, 2026 - - Podcast -
argenx partners with Monash University and Myostellar to develop muscular therapies
August 7, 2026 - - Latest News -
A new generation is rewriting their lives living with Cystic Fibrosis
August 7, 2026 - - Latest News -
US approves Moderna's mRNA flu vaccine in major technology milestone
August 7, 2026 - - Latest News -
If Australian companies shun their domestic market, who can blame multinationals?
August 6, 2026 - - Latest News -
Neuren reports record DAYBUE sales as royalties rise and global expansion nears
August 6, 2026 - - Australian Biotech -
Moderna begins Phase 1 trial of vaccine candidate against Bundibugyo Ebola Virus
August 6, 2026 - - Latest News

